参考文献/References:
[1] Rezzónico J,Rezzónico M,Pusiol E,et al. Metformin treatment for small benign thyroid nodules in patients with insulin resistance[J].Metab Syndr Relat Disord,2011,9(1):69-75. DOI:10.1089/met.2010.0026.
[2] Tseng CH. Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes[J].PLoS One,2014,9(10):e109852. DOI:10.1371/journal.pone.0109852.
[3] Klubo-Gwiezdzinska J,Costello J Jr,Patel A,et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer[J].J Clin Endocrinol Metab,2013,98(8):3269-3279.DOI:10.1210/jc.2012-3799.
[4] Cho SW,Yi KH,Han SK,et al.Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo[J].Mol Cell Endocrinol,2014,393(1-2):24-29.DOI:10.1016/j.mce.2014.05.021.
[5] Bikas A,Van Nostrand D,Jensen K,et al. Metformin attenuates 131I-induced decrease in peripheral blood cells in patients with differentiated thyroid cancer[J].Thyroid,2016,26(2):280-286.DOI:10.1089/thy.2015.0413.
[6] Jang EK,Kim WG,Kwon H,et al.Metformin is associated with a favorable outcome in diabetic patients with cervical lymph node metastasis of differentiated thyroid cancer[J].Eur Thyroid J,2015,4(3):181-188. DOI:10.1159/000437365.
[7] Becker C,Jick SS,Meier CR,et al.No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study[J].BMC Cancer,2015,15:719.DOI:10.1186/s12885-015-1719-6.
[8] Vigersky RA,Filmore-Nassar A,Glass AR. Thyrotropin suppression by metformin[J].J Clin Endocrinol Metab,2006,91(1):225-227.DOI:10.1210/jc.2005-1210.
[9] Lupoli R,Di Minno A,Tortora A,et al. Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies[J].J Clin Endocrinol Metab,2014,99(1):E143-E148.DOI:10.1210/jc.2013-2965.
[10] Fournier JP,Yin H,Yu OH,et al. Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus[J].CMAJ,2014,186(15):1138-1145.DOI:10.1503/cmaj.140688.
[11] Distiller LA,Polakow ES,Joffe BI. Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy[J].Diabet Med,2014,31(2):172-175.DOI:10.1111/dme.12342.
[12] Santos-Palacios S,Brugos-Larumbe A,Guillén-Grima F,et al. Does metformin have a "buffer effect" on serum TSH levels in euthyroid diabetic patients?[J].Hormones(Athens),2015,14(2):280-285.DOI:10.14310/horm.2002.1559.
[13] Karimifar M,Aminorroaya A,Amini M,et al. Effect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: a randomized placebo-controlled clinical trial[J].J Res Med Sci,2014,19(11):1019-1026.
[14] Krysiak R,Szkrobka W,Okopien B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism[J].Exp Clin Endocrinol Diabetes,2015,123(4):205-208. DOI:10.1055/s-0034-1398621.
[15] Casteràs A,Zafon C,Ciudin A,et al. Are levothyroxine requirements lower in thyroidectomized diabetic patients on metformin treatment?[J].Thyroid,2013,23(12):1510-1513.DOI:10.1089/thy.2013.0114.
[16] Mousavi Z,Dourandish L,Rokni H,et al. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer[J].Minerva Endocrinol,2014,39(1):59-65.
[17] Fontes R,Teixeira Pde F,Vaisman M. Screening of undiagnosed hypothyroidism in elderly persons with diabetes according to age-specific reference intervals for serum thyroid stimulating hormone and the impact of antidiabetes drugs[J].J Diabetes Res,2016,2016:1417408.DOI:10.1155/2016/1417408.
[18] Aschebrook-Kilfoy B,Sabra MM,Brenner A,et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health study[J].Thyroid,2011,21(9):957-963.DOI:10.1089/thy.2010.0396.
[19] Chen ST,Hsueh C,Chiou WK,et al. Disease-specific mortality and secondary primary cancer in well-differentiated thyroid cancer with type 2 diabetes mellitus[J].PLoS One,2013,8(1):e55179. DOI:10.1371/journal.pone.0055179.
[20] Anil C,Akkurt A,Ayturk S,et al. Impaired glucose metabolism is a risk factor for increased thyroid volume and nodule prevalence in a mild-to-moderate iodine deficient area[J].Metabolism,2013,62(7):970-975. DOI:10.1016/j.metabol.2013.01.009.
[21] Gursoy A.Rising thyroid cancer incidence in the world might be related to insulin resistance[J].Med Hypotheses,2010,74(1):35-36.DOI:10.1016/j.mehy.2009.08.021.
[22] Wang K,Yang Y,Wu Y,et al. The association between insulin resistance and vascularization of thyroid nodules[J].J Clin Endocrinol Metab,2015,100(1):184-192. DOI:10.1210/jc.2014-2723.
[23] Colin IM,Denef JF,Lengelé B,et al. Recent insights into the cell biology of thyroid angiofollicular units[J].Endocr Rev,2013,34(2):209-238.DOI:10.1210/er.2012-1015.
[24] Han B,Cui H,Kang L,et al.Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway[J].Tumour Biol,2015,36(8):6295-6304.DOI:10.1007/s13277-015-3315-4.
[25] Chen G,Xu S,Renko K,et al. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents[J].J Clin Endocrinol Metab,2012,97(4):E510-E520.DOI:10.1210/jc.2011-1754.
[26] Chen G,Nicula D,Renko K,et al. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells[J].Oncol Rep,2015,33(4):1994-2000.DOI:10.3892/or.2015.3805.
[27] 浮迎迎,陈国芳,李兴佳,等.二甲双胍通过microRNA/mTOR通路抑制甲状腺未分化癌细胞增殖[J]. 中华内分泌代谢杂志, 2017, 33(6):506-512. DOI:10.3760/cma.j.issn.1000-6699.2017.06.010.
[28] Klubo-Gwiezdzinska J,Jensen K,Costello J,et al.Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells[J].Endocr Relat Cancer,2012,19(3):447-456.DOI:10.1530/ERC-12-0046.
[29] Rotondi M,Coperchini F,Pignatti P,et al.Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug[J].J Clin Endocrinol Metab,2015,100(3):E427-E432.DOI:10.1210/jc.2014-3045.
相似文献/References:
[1]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[2]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[3]杨健姝,华飞,唐暎,等.二甲双胍在多囊卵巢综合征患者妊娠期的应用[J].国际内分泌代谢杂志,2014,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
Yang Jianshu,Hua Fei,Tang Ying,et al.The application of metformin in the pregnant patients with polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2014,(04):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
[4]翟丽敏,叶山东.二甲双胍的抗炎作用及其糖尿病肾脏保护作用[J].国际内分泌代谢杂志,2014,(05):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
Zhai Limin,Ye Shandong..Anti-inflammatory effects of metformin and its renal protection in diabetes[J].International Journal of Endocrinology and Metabolism,2014,(04):334.[doi:10.3760/cma.j.issn.1673-4157.2014.05.013]
[5]王隽书 杨光燃.亚临床甲状腺功能减退症动物模型的研究进展[J].国际内分泌代谢杂志,2018,38(04):247.[doi:10.3760/cma.j.issn.1673-4157.2018.04.007]
Wang Junshu,Yang Guangran..Recent progress of subclinical hypothyroidism animal models[J].International Journal of Endocrinology and Metabolism,2018,38(04):247.[doi:10.3760/cma.j.issn.1673-4157.2018.04.007]
[6]林杨 叶山东.二甲双胍对糖尿病肾病保护作用的机制[J].国际内分泌代谢杂志,2018,38(01):52.[doi:10.3760/cma.j.issn.1673-4157.2018.01.014]
Lin Yang*,Ye Shandong. *.Protective effects of metformin on diabetic nephropathy and its mechanism[J].International Journal of Endocrinology and Metabolism,2018,38(04):52.[doi:10.3760/cma.j.issn.1673-4157.2018.01.014]
[7]李静,李曙光,乐岭.二甲双胍抑制分化型甲状腺癌的作用及机制[J].国际内分泌代谢杂志,2021,41(01):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
Li Jing,Li Shuguang,Yue Ling..Effects and mechanisms of metformin on differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2021,41(04):28.[doi:10.3760/cma.j.cn121383-20200514-05032]
[8]王慧,李忠淑.二甲双胍联合恩替卡韦治疗2型糖尿病合并HBV感染并发NAFLD的疗效分析[J].国际内分泌代谢杂志,2022,42(02):124.[doi:10.3760/cma.j.cn121383-20200711-07031]
Wang Hui,Li Zhongshu..Therapeutic effect of metformin combined with entecavir on type 2 diabetes mellitus complicated with HBV infection and NAFLD[J].International Journal of Endocrinology and Metabolism,2022,42(04):124.[doi:10.3760/cma.j.cn121383-20200711-07031]
[9]《二甲双胍临床应用专家共识》更新专家组.二甲双胍临床应用专家共识(2023年版)[J].国际内分泌代谢杂志,2023,43(04):345.[doi:10.3760/cma.j.cn112138-20230305-00131]
Expert Group for Updating Chinese Expert Consensus on Metformin in Clinical Practice.Chinese Expert Consensus on Metformin in Clinical Practice: 2023 Update[J].International Journal of Endocrinology and Metabolism,2023,43(04):345.[doi:10.3760/cma.j.cn112138-20230305-00131]
[10]何志伟,黄文彬,杨雪,等.下丘脑-垂体-甲状腺轴对胰岛β细胞的调控作用[J].国际内分泌代谢杂志,2023,43(06):517.[doi:10.3760/cma.j.cn121383-20220928-09053]
He Zhiwei,Huang Wenbin,Yang Xue,et al.Regulation of the hypothalamic-pituitary-thyroid axis on islet β cells[J].International Journal of Endocrinology and Metabolism,2023,43(04):517.[doi:10.3760/cma.j.cn121383-20220928-09053]